Demographics of the study population
| . | Full population (n = 1434) . | HLA-B-leader matched (n = 878) . | HLA-B-leader mismatched (n = 556) . | . | HLA-DRB1 matched (n = 217) . | HLA-DRB1 mismatched (n = 1215) . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | n . | (%) . | n . | (%) . | n . | (%) . | P . | n . | (%) . | n . | (%) . | P . |
| Recipient age at transplant (yrs) | 0.53 | .13 | ||||||||||
| 0-10 | 49 | (3) | 24 | (3) | 25 | (4) | 7 | (3) | 42 | (3) | ||
| 10-17 | 73 | (5) | 42 | (5) | 31 | (6) | 8 | (4) | 65 | (5) | ||
| 18-29 | 159 | (11) | 92 | (10) | 67 | (12) | 17 | (8) | 142 | (12) | ||
| 30-39 | 135 | (9) | 83 | (9) | 52 | (9) | 13 | (6) | 121 | (10) | ||
| 40-49 | 195 | (14) | 123 | (14) | 72 | (13) | 30 | (14) | 165 | (14) | ||
| 50-59 | 313 | (22) | 195 | (22) | 118 | (21) | 57 | (26) | 256 | (21) | ||
| ≥60 | 510 | (36) | 319 | (36) | 191 | (34) | 85 | (39) | 424 | (35) | ||
| Median (range) | 54 | (1-78) | 55 | (1-78) | 53 | (1-78) | .12 | 57 | (1-78) | 53 | (1-78) | .004 |
| Sex | .95 | .67 | ||||||||||
| Male | 860 | (60) | 526 | (60) | 334 | (60) | 133 | (61) | 726 | (60) | ||
| Female | 574 | (40) | 352 | (40) | 222 | (40) | 84 | (39) | 489 | (40) | ||
| Disease | .96 | .20 | ||||||||||
| Acute myeloid leukemia | 831 | (58) | 509 | (58) | 322 | (58) | 136 | (63) | 693 | (57) | ||
| Acute lymphocytic leukemia | 334 | (23) | 206 | (23) | 128 | (23) | 41 | (19) | 293 | (24) | ||
| Myelodysplastic syndrome | 269 | (19) | 163 | (19) | 106 | (19) | 40 | (18) | 229 | (19) | ||
| Disease risk index | .68 | .79 | ||||||||||
| Low | 53 | (4) | 32 | (4) | 21 | (4) | 5 | (2) | 47 | (4) | ||
| Intermediate | 721 | (50) | 445 | (51) | 276 | (50) | 116 | (53) | 604 | (50) | ||
| Intermediate – cytogenetics not collected | 1 | (<1) | 1 | (<1) | 0 | 0 | 1 | (<1) | ||||
| High | 378 | (26) | 238 | (27) | 140 | (25) | 58 | (27) | 320 | (26) | ||
| Very high | 41 | (3) | 26 | (3) | 15 | (3) | 4 | (2) | 37 | (3) | ||
| N/A - no disease risk index for patient characteristics | 148 | (10) | 81 | (9) | 67 | (12) | 20 | (9) | 128 | (11) | ||
| Missing | 92 | (6) | 55 | (6) | 37 | (7) | 14 | (6) | 78 | (6) | ||
| Time from diagnosis to transplant | .53 | .45 | ||||||||||
| 0-6 mos | 728 | (51) | 455 | (52) | 273 | (49) | 117 | (54) | 610 | (50) | ||
| 7-12 mos | 325 | (23) | 192 | (22) | 133 | (24) | 44 | (20) | 281 | (23) | ||
| 1-2 y | 190 | (13) | 120 | (14) | 70 | (13) | 32 | (15) | 157 | (13) | ||
| Greater than 2 y | 191 | (13) | 111 | (13) | 80 | (14) | 24 | (11) | 167 | (14) | ||
| Race/Ethnicity | .57 | .11 | ||||||||||
| White, non-Hispanic | 812 | (57) | 503 | (57) | 309 | (56) | 125 | (58) | 685 | (56) | ||
| African American, non-Hispanic | 227 | (16) | 135 | (15) | 92 | (17) | 43 | (20) | 184 | (15) | ||
| Asian, non-Hispanic | 90 | (6) | 63 | (7) | 27 | (5) | 15 | (7) | 75 | (6) | ||
| Pacific islander, non-Hispanic | 6 | (<1) | 3 | (<1) | 3 | (1) | 0 | 6 | (<1) | |||
| Native American, non-Hispanic | 6 | (<1) | 3 | (<1) | 3 | (1) | 2 | (1) | 4 | (<1) | ||
| Hispanic, White | 212 | (15) | 126 | (14) | 86 | (15) | 19 | (9) | 193 | (16) | ||
| Hispanic, African American | 6 | (<1) | 4 | (<1) | 2 | (<1) | 1 | (<1) | 5 | (<1) | ||
| Missing | 75 | (5) | 41 | (5) | 34 | (6) | 12 | (6) | 63 | (5) | ||
| Donor/recipient cytomegalovirus serostatus | .61 | .95 | ||||||||||
| Positive/positive | 612 | (43) | 374 | (43) | 238 | (43) | 90 | (41) | 522 | (43) | ||
| Positive/negative | 119 | (8) | 74 | (8) | 45 | (8) | 18 | (8) | 101 | (8) | ||
| Negative/positive | 401 | (28) | 252 | (29) | 149 | (27) | 65 | (30) | 334 | (27) | ||
| Negative/negative | 292 | (20) | 174 | (20) | 118 | (21) | 43 | (20) | 249 | (20) | ||
| Missing | 10 | (1) | 4 | (<1) | 6 | (1) | 1 | (<1) | 9 | (1) | ||
| Hematopoietic cell transplantation comorbidity index | .12 | .57 | ||||||||||
| 0 | 302 | (21) | 197 | (22) | 105 | (19) | 51 | (24) | 250 | (21) | ||
| 1 | 210 | (15) | 115 | (13) | 95 | (17) | 26 | (12) | 184 | (15) | ||
| 2 | 210 | (15) | 128 | (15) | 82 | (15) | 32 | (15) | 178 | (15) | ||
| >3 | 712 | (50) | 438 | (50) | 274 | (49) | 108 | (50) | 603 | (50) | ||
| Karnofsky performance score (percent) | .31 | .11 | ||||||||||
| 10-80 | 577 | (40) | 343 | (39) | 234 | (42) | 98 | (44) | 477 | (39) | ||
| 90-100 | 814 | (57) | 506 | (58) | 308 | (55) | 113 | (52) | 701 | (58) | ||
| Missing | 43 | (3) | 29 | (3) | 14 | (3) | 6 | (3) | 37 | (3) | ||
| Graft type | .23 | .14 | ||||||||||
| Bone marrow | 614 | (43) | 387 | (44) | 227 | (41) | 83 | (38) | 530 | (44) | ||
| Peripheral blood | 820 | (57) | 491 | (56) | 329 | (59) | 134 | (62) | 685 | (56) | ||
| Conditioning regimen intensity | .77 | .020 | ||||||||||
| Myeloablative | 626 | (44) | 386 | (44) | 240 | (43) | 79 | (36) | 546 | (45) | ||
| Nonmyeloablative/reduced intensity | 808 | (56) | 492 | (56) | 316 | (57) | 138 | (64) | 669 | (55) | ||
| Donor relationship to recipient | .31 | .15 | ||||||||||
| Sibling | 321 | (22) | 199 | (23) | 122 | (22) | 39 | (18) | 282 | (23) | ||
| Parent | 140 | (10) | 85 | (10) | 55 | (10) | 14 | (6) | 126 | (10) | ||
| Child | 488 | (34) | 307 | (35) | 181 | (33) | 81 | (37) | 407 | (33) | ||
| Other relative | 15 | (1) | 9 | (1) | 6 | (1) | 3 | (1) | 12 | (1) | ||
| Not collected | 467 | (33) | 278 | (32) | 189 | (34) | 79 | (36) | 386 | (32) | ||
| Missing | 3 | (<1) | 0 | 3 | (1) | 1 | (<1) | 2 | (<1) | |||
| Donor age (yrs) | .26 | .33 | ||||||||||
| 0-19 | 128 | (9) | 68 | (8) | 60 | (11) | 16 | (7) | 112 | (9) | ||
| 20-29 | 343 | (24) | 204 | (23) | 139 | (25) | 55 | (25) | 286 | (24) | ||
| 30-39 | 411 | (29) | 260 | (30) | 151 | (27) | 51 | (24) | 360 | (30) | ||
| 40-49 | 310 | (22) | 192 | (22) | 118 | (21) | 55 | (25) | 255 | (21) | ||
| ≥50 | 240 | (17) | 152 | (17) | 88 | (16) | 40 | (18) | 200 | (16) | ||
| Missing | 2 | (<1) | 2 | (<1) | 0 | 0 | 2 | (<1) | ||||
| Median (range) | 35 | (2-73) | 36 | (2-73) | 35 | (9-73) | .05 | 36 | (4-73) | 35 | (2-73) | .32 |
| HLA-A match status | .82 | .57 | ||||||||||
| Matched | 264 | (18) | 160 | (18) | 104 | (19) | 37 | (17) | 227 | (19) | ||
| Mismatched | 1170 | (82) | 718 | (82) | 452 | (81) | 180 | (83) | 988 | (81) | ||
| HLA-B match status | <.001 | <.001 | ||||||||||
| Matched | 173 | (12) | 140 | (16) | 33 | (6) | 49 | (23) | 124 | (10) | ||
| Mismatched | 1261 | (88) | 738 | (84) | 523 | (94) | 168 | (77) | 1091 | (90) | ||
| HLA-B leader match status | .001 | |||||||||||
| Matched | 878 | (61) | 878 | (100) | 0 | (0) | 154 | (71) | 722 | (59) | ||
| Mismatched | 556 | (39) | 0 | (0) | 556 | (100) | 63 | (29) | 493 | (41) | ||
| HLA-C match status | <.001 | <.001 | ||||||||||
| Matched | 266 | (19) | 190 | (22) | 76 | (14) | 66 | (30) | 199 | (16) | ||
| Mismatched | 1168 | (81) | 688 | (78) | 480 | (86) | 151 | (70) | 1016 | (84) | ||
| HLA-DRB1 match status | .003 | |||||||||||
| Matched | 217 | (15) | 154 | (18) | 63 | (11) | 217 | (100) | 0 | (0) | ||
| Mismatched | 1215 | (85) | 722 | (82) | 493 | (89) | 0 | (0) | 1215 | (100) | ||
| Missing | 2 | (<1) | 2 | (<1) | 0 | (0) | 0 | (0) | 0 | (0) | ||
| HLA-DQB1 match status | .40 | <.001 | ||||||||||
| Matched | 401 | (28) | 250 | (28) | 151 | (27) | 168 | (77) | 231 | (19) | ||
| Mismatched | 1032 | (72) | 628 | (72) | 404 | (73) | 49 | (23) | 983 | (81) | ||
| Missing | 1 | (<1) | 0 | (0) | 1 | (<1) | 0 | (0) | 1 | (<1) | ||
| HLA-DPB1 match status | .25 | .14 | ||||||||||
| No nonpermissive GVH mismatch | 574 | (40) | 371 | (42) | 203 | (37) | 72 | (33) | 502 | (41) | ||
| Nonpermissive GVH mismatch | 103 | (7) | 57 | (6) | 46 | (8) | 15 | (7) | 88 | (7) | ||
| Missing | 757 | (53) | 450 | (51) | 307 | (55) | 130 | (60) | 625 | (51) | ||
| Follow-up among survivors | ||||||||||||
| No. evaluable | 774 | 492 | 282 | 110 | 662 | |||||||
| Median, mo (range) | 34 | (2-119) | 35 | (4-111) | 33 | (2-119) | .23 | 31 | (11-73) | 34 | (2-119) | .40 |
| . | Full population (n = 1434) . | HLA-B-leader matched (n = 878) . | HLA-B-leader mismatched (n = 556) . | . | HLA-DRB1 matched (n = 217) . | HLA-DRB1 mismatched (n = 1215) . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable . | n . | (%) . | n . | (%) . | n . | (%) . | P . | n . | (%) . | n . | (%) . | P . |
| Recipient age at transplant (yrs) | 0.53 | .13 | ||||||||||
| 0-10 | 49 | (3) | 24 | (3) | 25 | (4) | 7 | (3) | 42 | (3) | ||
| 10-17 | 73 | (5) | 42 | (5) | 31 | (6) | 8 | (4) | 65 | (5) | ||
| 18-29 | 159 | (11) | 92 | (10) | 67 | (12) | 17 | (8) | 142 | (12) | ||
| 30-39 | 135 | (9) | 83 | (9) | 52 | (9) | 13 | (6) | 121 | (10) | ||
| 40-49 | 195 | (14) | 123 | (14) | 72 | (13) | 30 | (14) | 165 | (14) | ||
| 50-59 | 313 | (22) | 195 | (22) | 118 | (21) | 57 | (26) | 256 | (21) | ||
| ≥60 | 510 | (36) | 319 | (36) | 191 | (34) | 85 | (39) | 424 | (35) | ||
| Median (range) | 54 | (1-78) | 55 | (1-78) | 53 | (1-78) | .12 | 57 | (1-78) | 53 | (1-78) | .004 |
| Sex | .95 | .67 | ||||||||||
| Male | 860 | (60) | 526 | (60) | 334 | (60) | 133 | (61) | 726 | (60) | ||
| Female | 574 | (40) | 352 | (40) | 222 | (40) | 84 | (39) | 489 | (40) | ||
| Disease | .96 | .20 | ||||||||||
| Acute myeloid leukemia | 831 | (58) | 509 | (58) | 322 | (58) | 136 | (63) | 693 | (57) | ||
| Acute lymphocytic leukemia | 334 | (23) | 206 | (23) | 128 | (23) | 41 | (19) | 293 | (24) | ||
| Myelodysplastic syndrome | 269 | (19) | 163 | (19) | 106 | (19) | 40 | (18) | 229 | (19) | ||
| Disease risk index | .68 | .79 | ||||||||||
| Low | 53 | (4) | 32 | (4) | 21 | (4) | 5 | (2) | 47 | (4) | ||
| Intermediate | 721 | (50) | 445 | (51) | 276 | (50) | 116 | (53) | 604 | (50) | ||
| Intermediate – cytogenetics not collected | 1 | (<1) | 1 | (<1) | 0 | 0 | 1 | (<1) | ||||
| High | 378 | (26) | 238 | (27) | 140 | (25) | 58 | (27) | 320 | (26) | ||
| Very high | 41 | (3) | 26 | (3) | 15 | (3) | 4 | (2) | 37 | (3) | ||
| N/A - no disease risk index for patient characteristics | 148 | (10) | 81 | (9) | 67 | (12) | 20 | (9) | 128 | (11) | ||
| Missing | 92 | (6) | 55 | (6) | 37 | (7) | 14 | (6) | 78 | (6) | ||
| Time from diagnosis to transplant | .53 | .45 | ||||||||||
| 0-6 mos | 728 | (51) | 455 | (52) | 273 | (49) | 117 | (54) | 610 | (50) | ||
| 7-12 mos | 325 | (23) | 192 | (22) | 133 | (24) | 44 | (20) | 281 | (23) | ||
| 1-2 y | 190 | (13) | 120 | (14) | 70 | (13) | 32 | (15) | 157 | (13) | ||
| Greater than 2 y | 191 | (13) | 111 | (13) | 80 | (14) | 24 | (11) | 167 | (14) | ||
| Race/Ethnicity | .57 | .11 | ||||||||||
| White, non-Hispanic | 812 | (57) | 503 | (57) | 309 | (56) | 125 | (58) | 685 | (56) | ||
| African American, non-Hispanic | 227 | (16) | 135 | (15) | 92 | (17) | 43 | (20) | 184 | (15) | ||
| Asian, non-Hispanic | 90 | (6) | 63 | (7) | 27 | (5) | 15 | (7) | 75 | (6) | ||
| Pacific islander, non-Hispanic | 6 | (<1) | 3 | (<1) | 3 | (1) | 0 | 6 | (<1) | |||
| Native American, non-Hispanic | 6 | (<1) | 3 | (<1) | 3 | (1) | 2 | (1) | 4 | (<1) | ||
| Hispanic, White | 212 | (15) | 126 | (14) | 86 | (15) | 19 | (9) | 193 | (16) | ||
| Hispanic, African American | 6 | (<1) | 4 | (<1) | 2 | (<1) | 1 | (<1) | 5 | (<1) | ||
| Missing | 75 | (5) | 41 | (5) | 34 | (6) | 12 | (6) | 63 | (5) | ||
| Donor/recipient cytomegalovirus serostatus | .61 | .95 | ||||||||||
| Positive/positive | 612 | (43) | 374 | (43) | 238 | (43) | 90 | (41) | 522 | (43) | ||
| Positive/negative | 119 | (8) | 74 | (8) | 45 | (8) | 18 | (8) | 101 | (8) | ||
| Negative/positive | 401 | (28) | 252 | (29) | 149 | (27) | 65 | (30) | 334 | (27) | ||
| Negative/negative | 292 | (20) | 174 | (20) | 118 | (21) | 43 | (20) | 249 | (20) | ||
| Missing | 10 | (1) | 4 | (<1) | 6 | (1) | 1 | (<1) | 9 | (1) | ||
| Hematopoietic cell transplantation comorbidity index | .12 | .57 | ||||||||||
| 0 | 302 | (21) | 197 | (22) | 105 | (19) | 51 | (24) | 250 | (21) | ||
| 1 | 210 | (15) | 115 | (13) | 95 | (17) | 26 | (12) | 184 | (15) | ||
| 2 | 210 | (15) | 128 | (15) | 82 | (15) | 32 | (15) | 178 | (15) | ||
| >3 | 712 | (50) | 438 | (50) | 274 | (49) | 108 | (50) | 603 | (50) | ||
| Karnofsky performance score (percent) | .31 | .11 | ||||||||||
| 10-80 | 577 | (40) | 343 | (39) | 234 | (42) | 98 | (44) | 477 | (39) | ||
| 90-100 | 814 | (57) | 506 | (58) | 308 | (55) | 113 | (52) | 701 | (58) | ||
| Missing | 43 | (3) | 29 | (3) | 14 | (3) | 6 | (3) | 37 | (3) | ||
| Graft type | .23 | .14 | ||||||||||
| Bone marrow | 614 | (43) | 387 | (44) | 227 | (41) | 83 | (38) | 530 | (44) | ||
| Peripheral blood | 820 | (57) | 491 | (56) | 329 | (59) | 134 | (62) | 685 | (56) | ||
| Conditioning regimen intensity | .77 | .020 | ||||||||||
| Myeloablative | 626 | (44) | 386 | (44) | 240 | (43) | 79 | (36) | 546 | (45) | ||
| Nonmyeloablative/reduced intensity | 808 | (56) | 492 | (56) | 316 | (57) | 138 | (64) | 669 | (55) | ||
| Donor relationship to recipient | .31 | .15 | ||||||||||
| Sibling | 321 | (22) | 199 | (23) | 122 | (22) | 39 | (18) | 282 | (23) | ||
| Parent | 140 | (10) | 85 | (10) | 55 | (10) | 14 | (6) | 126 | (10) | ||
| Child | 488 | (34) | 307 | (35) | 181 | (33) | 81 | (37) | 407 | (33) | ||
| Other relative | 15 | (1) | 9 | (1) | 6 | (1) | 3 | (1) | 12 | (1) | ||
| Not collected | 467 | (33) | 278 | (32) | 189 | (34) | 79 | (36) | 386 | (32) | ||
| Missing | 3 | (<1) | 0 | 3 | (1) | 1 | (<1) | 2 | (<1) | |||
| Donor age (yrs) | .26 | .33 | ||||||||||
| 0-19 | 128 | (9) | 68 | (8) | 60 | (11) | 16 | (7) | 112 | (9) | ||
| 20-29 | 343 | (24) | 204 | (23) | 139 | (25) | 55 | (25) | 286 | (24) | ||
| 30-39 | 411 | (29) | 260 | (30) | 151 | (27) | 51 | (24) | 360 | (30) | ||
| 40-49 | 310 | (22) | 192 | (22) | 118 | (21) | 55 | (25) | 255 | (21) | ||
| ≥50 | 240 | (17) | 152 | (17) | 88 | (16) | 40 | (18) | 200 | (16) | ||
| Missing | 2 | (<1) | 2 | (<1) | 0 | 0 | 2 | (<1) | ||||
| Median (range) | 35 | (2-73) | 36 | (2-73) | 35 | (9-73) | .05 | 36 | (4-73) | 35 | (2-73) | .32 |
| HLA-A match status | .82 | .57 | ||||||||||
| Matched | 264 | (18) | 160 | (18) | 104 | (19) | 37 | (17) | 227 | (19) | ||
| Mismatched | 1170 | (82) | 718 | (82) | 452 | (81) | 180 | (83) | 988 | (81) | ||
| HLA-B match status | <.001 | <.001 | ||||||||||
| Matched | 173 | (12) | 140 | (16) | 33 | (6) | 49 | (23) | 124 | (10) | ||
| Mismatched | 1261 | (88) | 738 | (84) | 523 | (94) | 168 | (77) | 1091 | (90) | ||
| HLA-B leader match status | .001 | |||||||||||
| Matched | 878 | (61) | 878 | (100) | 0 | (0) | 154 | (71) | 722 | (59) | ||
| Mismatched | 556 | (39) | 0 | (0) | 556 | (100) | 63 | (29) | 493 | (41) | ||
| HLA-C match status | <.001 | <.001 | ||||||||||
| Matched | 266 | (19) | 190 | (22) | 76 | (14) | 66 | (30) | 199 | (16) | ||
| Mismatched | 1168 | (81) | 688 | (78) | 480 | (86) | 151 | (70) | 1016 | (84) | ||
| HLA-DRB1 match status | .003 | |||||||||||
| Matched | 217 | (15) | 154 | (18) | 63 | (11) | 217 | (100) | 0 | (0) | ||
| Mismatched | 1215 | (85) | 722 | (82) | 493 | (89) | 0 | (0) | 1215 | (100) | ||
| Missing | 2 | (<1) | 2 | (<1) | 0 | (0) | 0 | (0) | 0 | (0) | ||
| HLA-DQB1 match status | .40 | <.001 | ||||||||||
| Matched | 401 | (28) | 250 | (28) | 151 | (27) | 168 | (77) | 231 | (19) | ||
| Mismatched | 1032 | (72) | 628 | (72) | 404 | (73) | 49 | (23) | 983 | (81) | ||
| Missing | 1 | (<1) | 0 | (0) | 1 | (<1) | 0 | (0) | 1 | (<1) | ||
| HLA-DPB1 match status | .25 | .14 | ||||||||||
| No nonpermissive GVH mismatch | 574 | (40) | 371 | (42) | 203 | (37) | 72 | (33) | 502 | (41) | ||
| Nonpermissive GVH mismatch | 103 | (7) | 57 | (6) | 46 | (8) | 15 | (7) | 88 | (7) | ||
| Missing | 757 | (53) | 450 | (51) | 307 | (55) | 130 | (60) | 625 | (51) | ||
| Follow-up among survivors | ||||||||||||
| No. evaluable | 774 | 492 | 282 | 110 | 662 | |||||||
| Median, mo (range) | 34 | (2-119) | 35 | (4-111) | 33 | (2-119) | .23 | 31 | (11-73) | 34 | (2-119) | .40 |